ClinicalTrials.gg
CompletedNCT04725240Updated Feb 7, 2025Results posted

Open-Label Study of Setmelanotide in Hypothalamic Obesity

A Phase 2 interventional study of Setmelanotide in Hypothalamic Obesity, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 5 sites in United States. Open to participants aged 6 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-02-07.

Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
6 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Sexual Infantilism with a site in United States — 3 open to participants now, 6 under way, 2 of them phase 3. Sexual Infantilism · United States.

Enrollment
11th of 14
18 · median 27
Started
2021
with 1 other
Phase 2
7 of 14
1 open now
Registered
5th of 14
by date
Lead sponsor
7 of 14
Rhythm Pharmaceuticals, Inc.

Among the 14 studies in Sexual Infantilism with a site in United States, this one is the 11th largest by enrollment, is one of 2 that started in 2021, is one of 7 in phase 2, and was the 5th registered.

Sexual Infantilism

23 studies on the registry are indexed under Sexual Infantilism; 5 are open to participants now.

Browse Sexual Infantilism studies →

Open to participants now

3 of the 14 studies in Sexual Infantilism with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Sexual Infantilism studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 6 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Sexual Infantilism with a site in United States, or all of them as a file.
02

Study summary

Open-label, single-arm study designed to evaluate the body weight response to setmelanotide administered subcutaneously (SC) daily in participants with hypothalamic obesity (HO).

03

Conditions studied

  • Hypothalamic Obesity

Browse trials for

04

Who can participate

Ages eligible
6 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following criteria to be eligible for study participation:

  • Participant has documented evidence of HO, including:

    • Recent evidence of hypothalamic injury on magnetic resonance imaging (MRI); AND
    • Diagnosis of craniopharyngioma or other non-malignant brain tumor affecting the hypothalamic region; AND
    • Has undergone surgery, or chemotherapy, or radiation ≥6 months and ≤15 years before Screening.
  • Participant has either unilateral hypothalamic lesions or bilateral hypothalamic lesions, as assessed by MRI.
  • Obesity, documented by a (BMI) ≥35 kilograms/square meter (kg/m\^2) for participants ≥18 years of age or BMI ≥95th percentile for age and gender for participants 6 to \<18 years of age.
  • Documented increase in BMI (change from pre-surgery baseline in BMI z-score ≥0.2 for participants \<18 years of age or BMI >5% for participants >18 years of age) either during the first 6 months following surgery or within 1 year before surgery AND still present at Screening.
  • More than 6 months after the end of post-tumor treatment, including chemotherapy, surgery, or radiation.
  • Highly effective throughout the study and for 90 days following the study.
  • Ability to communicate well with the Investigator, understand and comply with the requirements of the study, and understand and sign the written , or, for participants aged \<18 years, a parent/legal guardian that can sign.
  • If receiving hormone replacement therapy, the dose of such therapy has remained stable for at least 2 months prior to Screening.

Exclusion criteria

Exclusion Criteria:

Participants meeting any of the following criteria are not eligible for study participation:

  • Weight gain >5% in the previous 3 months.
  • Weight loss ≥2% in the previous 3 months.
  • Bariatric surgery or procedure within the last 6 months.
  • Diagnosis of severe psychiatric disorders
  • (HbA1c) >10.0% at Screening.
  • Current, pulmonary, cardiac, or oncologic disease considered severe enough to interfere with the study and/or confound the results.
  • (GFR) \<30mL/min/1.73m\^2 during Screening.
  • Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions.
  • History or close family history (parents or siblings) of skin cancer or melanoma
  • Participation in any clinical study with an drug/device within 3 months or 5 half-lives, whichever is longer, prior to the first setmelanotide dose.
  • Previously enrolled in a clinical study involving setmelanotide or any previous exposure to setmelanotide.
  • Inability to comply with QD injection regimen.
  • Pregnant and/or breastfeeding, or desiring to become pregnant during this trial.
  • Cognitive impairment that, in the Investigator's opinion, precludes participation to the study and completions of study procedures or questionnaires.
  • Participant is, in Investigator's opinion, otherwise not suitable to participate in the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Setmelanotide

    Participants received setmelanotide once daily (QD) via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and dose escalated up to a maximum dose of 3.0 milligrams (mg) QD.

    Drug: Setmelanotide

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With ≥ 5% Reduction in BMI From Baseline After 16 Weeks of Setmelanotide Treatment

    BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. Baseline was defined as the most recent measurement prior to the first administration of study drug.

    Time frame: Baseline to 16 weeks

Secondary outcomes

  1. Composite Percentage of Participants Aged ≥6 to <18 Years With ≥0.2 Reduction of BMI Z-Score or Participants Aged ≥18 Years With 5% Reduction of Body Weight From Baseline After 16 Weeks of Setmelanotide Treatment

    For participants aged ≥6 to \<18 years, a participant's BMI Z-score was considered for the analysis; for participants ≥18 years, a participant's body weight (kg) was considered for the analysis. BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. The BMI Z-score indicated the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease of BMI Z-score indicates a reduction in BMI from Baseline whereas an increase of BMI-Z score indicates an increase in BMI from Baseline. Baseline was defined as the most recent measurement prior to the first administration of study drug.

    Time frame: Baseline to Week 16

  2. Percentage of Participants Aged ≥6 to <18 Years With ≥0.2 Reduction of BMI Z-Score From Baseline After 16 Weeks of Setmelanotide Treatment

    BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. The BMI Z-score indicated the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease of BMI Z-score indicates a reduction in BMI from Baseline whereas an increase of BMI-Z score indicates an increase in BMI from Baseline. Baseline was defined as the most recent measurement prior to the first administration of study drug.

    Time frame: Baseline to 16 weeks

  3. Percentage of Participants Aged ≥18 Years With ≥5% Reduction of Body Weight From Baseline After 16 Weeks of Setmelanotide Treatment

    Baseline was defined as the most recent measurement prior to the first administration of study drug.

    Time frame: Baseline to Week 16

  4. Change From Baseline in Waist Circumference in Participants Aged ≥18 Years After 16 Weeks of Setmelanotide Treatment

    Waist circumference was measured after participants had fasted for at least 8 hours and at approximately the same time at each visit. Baseline was defined as the most recent measurement prior to the first administration of study drug.

    Time frame: Baseline, Week 16

  5. Change From Baseline in Daily Hunger Questionnaire Score in Participants Aged <12 Years After 16 Weeks of Setmelanotide Treatment

    Daily Hunger Questionnaire for participants \<12 years of age: Three aspects of hunger (average hunger in the last 24 hours, most/worst hunger in the last 24 hours, and morning hunger) were assessed daily using a pictorial (smiley face) version of the Likert rating scale with scores from 0 to 4, with 0 = not hungry at all and 4 = hungriest possible. Responses were recorded in the electronic diary. Each of the 3 items (average hunger, most/worst hunger, and morning hunger) was scored separately and averaged to calculate a total score ranging from 0 (not hungry at all) to 4 (hungriest possible) with higher score indicating more hunger. Baseline daily hunger score was calculated as the average of 7 days prior to Baseline visit.

    Time frame: Baseline, Week 16

  6. Change From Baseline in Daily Hunger Questionnaire Scores in Participants Aged ≥12 Years After 16 Weeks of Setmelanotide Treatment

    Daily Hunger Questionnaire for participants ≥12 years of age: Three aspects of hunger (average hunger in the last 24 hours, most/worst hunger in the last 24 hours, and morning hunger) were assessed daily using a numeric rating score for each from 0 to 10, with 0 = not hungry at all and 10 = hungriest possible. The responses to the Daily Hunger Questionnaire were recorded in the electronic diary. Baseline daily hunger score was calculated as the average of 7 days prior to Baseline visit.

    Time frame: Baseline, Week 16

  7. Number of Participants With Shift From Baseline in Global Hunger Questionnaire Score to Week 16 in Participants Aged < 12 Years

    Parents or caregivers of participants \<12 years old answered the Caregiver Reported Global Hunger Question for participants who were \<12 years old. The following question was asked: How hungry is your child acting now? Possible responses were: Not hungry at all; A little hungry; Moderately hungry; and Extremely hungry. Baseline was defined as the most recent measurement prior to the first administration of study drug.

    Time frame: Baseline, Week 16

  8. Number of Participants With Shift From Baseline in Global Hunger Questionnaire Score to Week 16 in Participants Aged ≥12 Years

    Global Hunger Questionnaire for participants ≥12 years of age. The following question was asked: Overall, how would you rate the hunger you experience now? Possible responses were: No hunger; Mild hunger; Moderate hunger; and Severe hunger. Baseline was defined as the most recent measurement prior to the first administration of study drug.

    Time frame: Baseline, Week 16

  9. Number of Participants With Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence or clinically significant worsening of an existing condition associated with the use of a drug in humans, whether or not considered drug related. An AE (also referred to as an adverse experience) could be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, without any judgment about causality.

    Time frame: From first dose of study drug up to Day 141

07

Results

Posted Sep 21, 2023

Participant flow

Participant flow — Overall Study
MilestoneSetmelanotide
Started18
Completed16
Not completed2
Withdrew: Adverse event2

Outcome measures

PrimaryPercentage of Participants With ≥ 5% Reduction in BMI From Baseline After 16 Weeks of Setmelanotide Treatment

BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. Baseline was defined as the most recent measurement prior to the first administration of study drug.

Time frame:
Baseline to 16 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With ≥ 5% Reduction in BMI From Baseline After 16 Weeks of Setmelanotide Treatment
percentage of participantsSetmelanotide
Percentage of Participants With ≥ 5% Reduction in BMI From Baseline After 16 Weeks of Setmelanotide Treatment88.9 (69.0 to 98.0)
Statistical analysis
  • Setmelanotide · One-sided exact binomial test · p = <0.0001 (Threshold for significance at 0.001 level.)
SecondaryComposite Percentage of Participants Aged ≥6 to <18 Years With ≥0.2 Reduction of BMI Z-Score or Participants Aged ≥18 Years With 5% Reduction of Body Weight From Baseline After 16 Weeks of Setmelanotide Treatment

For participants aged ≥6 to \<18 years, a participant's BMI Z-score was considered for the analysis; for participants ≥18 years, a participant's body weight (kg) was considered for the analysis. BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. The BMI Z-score indicated the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease of BMI Z-score indicates a reduction in BMI from Baseline whereas an increase of BMI-Z score indicates an increase in BMI from Baseline. Baseline was defined as the most recent measurement prior to the first administration of study drug.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Composite Percentage of Participants Aged ≥6 to <18 Years With ≥0.2 Reduction of BMI Z-Score or Participants Aged ≥18 Years With 5% Reduction of Body Weight From Baseline After 16 Weeks of Setmelanotide Treatment
percentage of participantsSetmelanotide
Composite Percentage of Participants Aged ≥6 to <18 Years With ≥0.2 Reduction of BMI Z-Score or Participants Aged ≥18 Years With 5% Reduction of Body Weight From Baseline After 16 Weeks of Setmelanotide Treatment88.9 (69.0 to 98.0)
Statistical analysis
  • Setmelanotide · One-sided exact binomial test · p = <0.0001 (Threshold for significance at 0.001 level.)
SecondaryPercentage of Participants Aged ≥6 to <18 Years With ≥0.2 Reduction of BMI Z-Score From Baseline After 16 Weeks of Setmelanotide Treatment

BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. The BMI Z-score indicated the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease of BMI Z-score indicates a reduction in BMI from Baseline whereas an increase of BMI-Z score indicates an increase in BMI from Baseline. Baseline was defined as the most recent measurement prior to the first administration of study drug.

Time frame:
Baseline to 16 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Aged ≥6 to <18 Years With ≥0.2 Reduction of BMI Z-Score From Baseline After 16 Weeks of Setmelanotide Treatment
percentage of participantsSetmelanotide
Percentage of Participants Aged ≥6 to <18 Years With ≥0.2 Reduction of BMI Z-Score From Baseline After 16 Weeks of Setmelanotide Treatment92.3 (68.4 to 99.6)
Statistical analysis
  • Setmelanotide · One-sided exact binomial test · p = <0.0001 (Threshold for significance at 0.001 level.)
SecondaryPercentage of Participants Aged ≥18 Years With ≥5% Reduction of Body Weight From Baseline After 16 Weeks of Setmelanotide Treatment

Baseline was defined as the most recent measurement prior to the first administration of study drug.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Aged ≥18 Years With ≥5% Reduction of Body Weight From Baseline After 16 Weeks of Setmelanotide Treatment
percentage of participantsSetmelanotide
Percentage of Participants Aged ≥18 Years With ≥5% Reduction of Body Weight From Baseline After 16 Weeks of Setmelanotide Treatment80.0 (34.3 to 99.0)
Statistical analysis
  • Setmelanotide · One-sided exact binomial test · p = <0.0001 (Threshold for significance at 0.001 level.)
SecondaryChange From Baseline in Waist Circumference in Participants Aged ≥18 Years After 16 Weeks of Setmelanotide Treatment

Waist circumference was measured after participants had fasted for at least 8 hours and at approximately the same time at each visit. Baseline was defined as the most recent measurement prior to the first administration of study drug.

Time frame:
Baseline, Week 16
Reported as:
Mean · cm
Change From Baseline in Waist Circumference in Participants Aged ≥18 Years After 16 Weeks of Setmelanotide Treatment
cmSetmelanotide
Change From Baseline in Waist Circumference in Participants Aged ≥18 Years After 16 Weeks of Setmelanotide Treatment-10.275 ± 4.2272
SecondaryChange From Baseline in Daily Hunger Questionnaire Score in Participants Aged <12 Years After 16 Weeks of Setmelanotide Treatment

Daily Hunger Questionnaire for participants \<12 years of age: Three aspects of hunger (average hunger in the last 24 hours, most/worst hunger in the last 24 hours, and morning hunger) were assessed daily using a pictorial (smiley face) version of the Likert rating scale with scores from 0 to 4, with 0 = not hungry at all and 4 = hungriest possible. Responses were recorded in the electronic diary. Each of the 3 items (average hunger, most/worst hunger, and morning hunger) was scored separately and averaged to calculate a total score ranging from 0 (not hungry at all) to 4 (hungriest possible) with higher score indicating more hunger. Baseline daily hunger score was calculated as the average of 7 days prior to Baseline visit.

Time frame:
Baseline, Week 16
Reported as:
Mean · units on a scale
Change From Baseline in Daily Hunger Questionnaire Score in Participants Aged <12 Years After 16 Weeks of Setmelanotide Treatment
units on a scaleSetmelanotide
Change From Baseline in Daily Hunger Questionnaire Score in Participants Aged <12 Years After 16 Weeks of Setmelanotide Treatment-1.490 ± 1.2126
SecondaryChange From Baseline in Daily Hunger Questionnaire Scores in Participants Aged ≥12 Years After 16 Weeks of Setmelanotide Treatment

Daily Hunger Questionnaire for participants ≥12 years of age: Three aspects of hunger (average hunger in the last 24 hours, most/worst hunger in the last 24 hours, and morning hunger) were assessed daily using a numeric rating score for each from 0 to 10, with 0 = not hungry at all and 10 = hungriest possible. The responses to the Daily Hunger Questionnaire were recorded in the electronic diary. Baseline daily hunger score was calculated as the average of 7 days prior to Baseline visit.

Time frame:
Baseline, Week 16
Reported as:
Mean · units on a scale
Change From Baseline in Daily Hunger Questionnaire Scores in Participants Aged ≥12 Years After 16 Weeks of Setmelanotide Treatment
units on a scaleSetmelanotide
Most hunger-2.922 ± 2.2851
Average hunger-3.122 ± 1.9999
Morning hunger-2.717 ± 1.9393
SecondaryNumber of Participants With Shift From Baseline in Global Hunger Questionnaire Score to Week 16 in Participants Aged < 12 Years

Parents or caregivers of participants \<12 years old answered the Caregiver Reported Global Hunger Question for participants who were \<12 years old. The following question was asked: How hungry is your child acting now? Possible responses were: Not hungry at all; A little hungry; Moderately hungry; and Extremely hungry. Baseline was defined as the most recent measurement prior to the first administration of study drug.

Time frame:
Baseline, Week 16
Reported as:
Count of participants · Participants
Number of Participants With Shift From Baseline in Global Hunger Questionnaire Score to Week 16 in Participants Aged < 12 Years
ParticipantsSetmelanotide
Not hungry at all (Baseline) - Not hungry at all (Week 16)0
A little hungry (Baseline) - Not hungry at all (week 16)0
Moderately hungry (Baseline) - Not hungry at all (Week 16)0
Extremely hungry (Baseline) - Not hungry at all (Week 16)2
Not hungry at all (Baseline) - A little hungry (Week 16)0
A little hungry (Baseline) - A little hungry (Week 16)0
Moderately hungry (Baseline) - A little hungry (Week 16)1
Extremely hungry (Baseline) - A little hungry (Week 16)2
Not hungry at all (Baseline) - Moderately hungry (Week 16)0
A little hungry (Baseline) - Moderately hungry (Week 16)0
Moderately hungry (Baseline) - Moderately hungry (Week 16)0
Extremely hungry (Baseline) - Moderately hungry (Week 16)0
Not hungry at all (Baseline) - Extremely hungry (Week 16)0
A little hungry (Baseline) - Extremely hungry (Week 16)0
Moderately hungry (Baseline) - Extremely hungry (Week 16)0
Extremely hungry (Baseline) - Extremely hungry (Week 16)0
SecondaryNumber of Participants With Shift From Baseline in Global Hunger Questionnaire Score to Week 16 in Participants Aged ≥12 Years

Global Hunger Questionnaire for participants ≥12 years of age. The following question was asked: Overall, how would you rate the hunger you experience now? Possible responses were: No hunger; Mild hunger; Moderate hunger; and Severe hunger. Baseline was defined as the most recent measurement prior to the first administration of study drug.

Time frame:
Baseline, Week 16
Reported as:
Count of participants · Participants
Number of Participants With Shift From Baseline in Global Hunger Questionnaire Score to Week 16 in Participants Aged ≥12 Years
ParticipantsSetmelanotide
No hunger (Baseline) - No hunger (Week 16)0
Mild hunger (Baseline) - No hunger (Week 16)1
Moderate hunger (Baseline) - No hunger (Week 16)3
Severe hunger (Baseline) - No hunger (Week 16)0
No hunger (Baseline) - Mild hunger (Week 16)1
Mild hunger (Baseline) - Mild hunger (Week 16)0
Moderate hunger (Baseline) - Mild hunger (Week 16)3
Severe hunger (Baseline) - Mild hunger (Week 16)2
No hunger (Baseline) - Moderate hunger (Week 16)0
Mild hunger (Baseline) - Moderate hunger (Week 16)0
Moderate hunger (Baseline) - Moderate hunger (Week 16)1
Severe hunger (Baseline) - Moderate hunger (Week 16)0
No hunger (Baseline) - Severe hunger (Week 16)0
Mild hunger (Baseline) - Severe hunger (Week 16)0
Moderate hunger (Baseline) - Severe hunger (Week 16)0
Severe hunger (Baseline) - Severe hunger (Week 16)0
SecondaryNumber of Participants With Adverse Events (AEs)

An AE was defined as any untoward medical occurrence or clinically significant worsening of an existing condition associated with the use of a drug in humans, whether or not considered drug related. An AE (also referred to as an adverse experience) could be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, without any judgment about causality.

Time frame:
From first dose of study drug up to Day 141
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsSetmelanotide
Number of Participants With Adverse Events (AEs)18

Adverse events

Collected over From first dose of study drug up to Day 141. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Setmelanotide0/18 (0%)1/18 (5.6%)18/18 (100%)
Most frequent serious events
Most frequent serious events
EventSetmelanotide
Clostridium difficile colitisInfections and infestations1/18
Most frequent other events
Showing 10 of 50
Most frequent other events
EventSetmelanotide
NauseaGastrointestinal disorders11/18
VomitingGastrointestinal disorders6/18
Skin hyperpigmentationSkin and subcutaneous tissue disorders6/18
Erection increasedReproductive system and breast disorders3/11
DiarrhoeaGastrointestinal disorders4/18
COVID-19Infections and infestations4/18
FatigueGeneral disorders3/18
Injection site painGeneral disorders3/18
Abdominal painGastrointestinal disorders3/18
Injection site pruritusGeneral disorders2/18

Baseline characteristics

The Full Analysis Set included all participants who received at least 1 dose of setmelanotide and had baseline data.

Age, Continuous
Age, Continuous(years)Setmelanotide
Mean15.0 ± 5.30
Sex: Female, Male
Sex: Female, Male(Participants)Setmelanotide
Female7
Male11
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Setmelanotide
Hispanic or Latino4
Not Hispanic or Latino14
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Setmelanotide
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander1
Black or African American3
White14
More than one race0
Unknown or Not Reported0
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms/square meter (kg/m^2))Setmelanotide
Mean37.95 ± 6.532
Body Weight
Body Weight(kilograms (kg))Setmelanotide
Mean102.76 ± 30.120
BMI Z-Score
BMI Z-Score(z-score)Setmelanotide
Mean3.935 ± 0.9080
Waist Circumference
Waist Circumference(centimeters (cm))Setmelanotide
Mean114.07 ± 16.354
08

Study locations

5 sites
  • Rady Children's Hospital
    San Diego, California 92123, United States
  • University of Florida
    Gainesville, Florida 32610-0296, United States
  • Children's Minnesota
    Saint Paul, Minnesota 55102, United States
  • Vanderbilt University School of Medicine
    Nashville, Tennessee 37232, United States
  • Seattle Children's Research Institute
    Seattle, Washington 98101, United States
09

References and documents

Publications

  • Roth CL, Scimia C, Shoemaker AH, Gottschalk M, Miller J, Yuan G, Malhotra S, Abuzzahab MJ. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial. Lancet Diabetes Endocrinol. 2024 Jun;12(6):380-389. doi: 10.1016/S2213-8587(24)00087-1. Epub 2024 Apr 30. PubMed 38697184 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Jun 2022, 12 months.

Results were first posted in Sep 2023, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2021
First posted
Jan 26, 2021
StartActual
Jun 7, 2021
Primary completionActual
Jun 28, 2022
CompletionActual
Jun 28, 2022
Results first posted
Sep 21, 2023
Last update
Feb 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04725240
Responsible party
Sponsor
First posted
Jan 26, 2021
Start date
Jun 7, 2021
Primary completion
Jun 28, 2022
Completion
Jun 28, 2022
Results posted
Sep 21, 2023
Last update
Feb 7, 2025

Study contacts

David Meeker, MD
study chair · Rhythm Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Setmelanotide

Start the discussion